Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
DVA stock benefits from a patient-centric model, third-quarter revenue growth and overseas expansion, though reliance on commercial payers remains a risk.
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
DaVita HealthCare (DVA) closed the most recent trading day at $104.47, moving 5.11% from the previous trading session.
Why DaVita HealthCare (DVA) Dipped More Than Broader Market Today
DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its last close.
DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.
4 Outpatient Home Health Stocks in Focus as Market Dynamics Change
An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.
DaVita: More Volatile But Better Upside Than Fresenius
DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.
DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe Research, LLC Presentation Justin Lake Wolfe Research, LLC All right. Good morning.
3 Warren Buffett Stocks to Buy Hand Over Fist in November
DaVita is cheap considering its long-term growth potential. Buy Kraft Heinz for its high yield, stay for the restructuring that could unlock the food company's underlying value.
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript
DaVita Inc. ( DVA ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Nic Eliason - Group Vice President of Investor Relations Javier Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Conference Call Participants Kevin Fischbeck - BofA Securities, Research Division Andrew Mok - Barclays Bank PLC, Research Division Albert Rice - UBS Investment Bank, Research Division Pito Chickering - Deutsche Bank AG, Research Division Justin Lake - Wolfe Research, LLC Ryan Langston - TD Cowen, Research Division Presentation Operator Good evening. My name is Michelle, and I will be your conference facilitator today.
DaVita HealthCare (DVA) Q3 Earnings Lag Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $2.59 per share a year ago.
